Learn More >

Ministry Status: Activation Status

Ontario Public Drug Programs

Glossary – D

This glossary provides brief explanations of terms used in the Ontario Public Drug Programs web pages. To access a term definition, select the appropriate letter from the alphabet below.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
DIDFA See Drug Interchangeability and Dispensing Fee Act
Disease-free survival Time from clinical trial randomization until recurrence of disease or until death from any cause. Disease-free survival is sometimes used in clinical studies to assess the efficacy of a treatment, especially in situations where survival may be prolonged, making measurement of overall survival impractical. (See overall survival.)
Double-blind study

A clinical trial designed so that neither the participating individuals nor the study staff knows which participants receive the experimental drug and which receive the placebo or standard of therapy. (See Placebo).

Blinding ensures that investigator preferences or expectations, or participants' desire to please investigators or hope of improvement, does not influence and distort results. See single-blind.

DRD See Drugs for Rare Diseases.
Drug Interchangeability and Dispensing Fee Act (DIDFA) The Drug Interchangeability and Dispensing Fee Act and its accompanying regulations, Ontario Regulations 935 and 936, govern the designation of drugs as interchangeable in the ODB Formulary.
Drugs for Rare Diseases

In the absence of a national strategy, the Ontario Ministry of Health has developed a framework for Drugs for Rare Diseases (DRDs).  This framework recognizes that an innovative approach is required for DRDs, which considers the level of available clinical evidence, patient need, and reimbursement.
The approach is based on the “best available evidence” to assist us in predicting the potential benefit or lack of benefit of a drug treatment in specific patients.  This new approach will help identify groups of individuals that may potentially benefit from treatment with a particular drug, and where we may consider funding.

The ministry is using the draft DRD framework to assess funding requests for DRDs.  Ontario is leveraging its own work and experience to date to support a national (P/T) approach to evaluate drugs for rare diseases for public funding purposes.

For More Information

Call ServiceOntario, Infoline at:
1-866-532-3161 (Toll-free)
In Toronto, (416) 314-5518
TTY 1-800-387-5559.
In Toronto, TTY 416-327-4282
Hours of operation : Monday to Friday, 8:30am - 5:00pm